Explore Current Clinical Trials
If you are new to clinical trials, the first step is to let your transplant team know that you would like more information about clinical trials. TransplantLyfe has provided these educational materials below to help better inform you about the process and concepts in the clinical trials above.
- Link to articles once published
- Link to articles once published
- Etc.
You and your doctor may decide that a clinical trial is a good option to explore for your treatment. Below are two studies, which are currently enrolling. For more information, please contact the study investigators provided in the links below and consult your transplant team.
Kidney Transplant Clinical Trials Currently Enrolling
You and your doctor may decide that a clinical trial is a good option to explore for your treatment. Below are two studies, which are currently enrolling. For more information, please contact the study investigators provided in the links below and consult your transplant team.
The Ascend Study aims to test the safety and effectiveness of our investigational drug, siplizumab, given together with three FDA-approved treatments for kidney transplant patients: belatacept, mycophenolate (MPA), and steroids, compared to the standard drugs patients receive after kidney transplant.
For more information please visit:
View study on clinicaltrials.gov
Learn more about ITB-MED
A safety and tolerability study of TCD601 (siplizumab), a human anti-CD2 antibody, combined with donor bone marrow cell infusion and non-myeloablative conditioning, including fludarabine and cyclophosphamide, for tolerance induction in de novo living donor renal transplantation.
The Ascend Study aims to test the safety and effectiveness of our investigational drug, siplizumab, given together with three FDA-approved treatments for kidney transplant patients: belatacept, mycophenolate (MPA), and steroids, compared to the standard drugs patients receive after kidney transplant.
For more information please visit:
View study on clinicaltrials.gov
Learn more about ITB-MED
Ascend
The Ascend Study aims to test the safety and effectiveness of our investigational drug, siplizumab, given together with three FDA-approved treatments for kidney transplant patients: belatacept, mycophenolate (MPA), and steroids, compared to the standard drugs patients receive after kidney transplant.
For more information please visit:
View study on clinicaltrials.gov
Learn more about ITB-MED
Ascend
The Ascend Study aims to test the safety and effectiveness of our investigational drug, siplizumab, given together with three FDA-approved treatments for kidney transplant patients: belatacept, mycophenolate (MPA), and steroids, compared to the standard drugs patients receive after kidney transplant.
For more information please visit:
View study on clinicaltrials.gov
Learn more about ITB-MED
The Ascend Study aims to test the safety and effectiveness of our investigational drug, siplizumab, given together with three FDA-approved treatments for kidney transplant patients: belatacept, mycophenolate (MPA), and steroids, compared to the standard drugs patients receive after kidney transplant.
For more information please visit:
View study on clinicaltrials.gov
Learn more about ITB-MED
The Ascend Study aims to test the safety and effectiveness of our investigational drug, siplizumab, given together with three FDA-approved treatments for kidney transplant patients: belatacept, mycophenolate (MPA), and steroids, compared to the standard drugs patients receive after kidney transplant.
For more information please visit:
View study on clinicaltrials.gov
Learn more about ITB-MED